Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in healthy participants of Japanese descent.
Key facts
- Study ID
- NCT04952545
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 20
- Starts
- 2021-07-09
- Expected to finish
- 2021-09-07
- Last updated by the study team
- 2022-12-09
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Trial Site — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.